Thank you for your interest in submitting an abstract for consideration of an electronic poster (E-Poster) at the ECG Interpretation Nuts & Bolts from Analysis to Management 2026. Please complete the fields below and click submit at the end of the form. You should receive a confirmation e-mail after you click submit. Submissions are due by February 6, 2026

Specific topics of interest include: presentation of original research dedicated to the field of diagnosis, evaluation, and treatment of cardiac rhythm disorders.

You will be notified by February 13, 2026, if your abstract has been accepted, at which time you will receive additional information regarding your participation at the live course on March 3-7, 2026.

Individual Information
*
*
*
*
*
Abstract Specific Information
*
*
*
*
Please attach any additional documentation here. PDF only.
Files must be less than 2 MB.
Allowed file types: pdf.

Comments

Jenna Davison replied on

References:

  1. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of cases with ventricular arrhythmias and the prevention of sudden cardiac death. Circ. 2018;138:e272–e391. 

  1. Nordenswan HK, Lehtonen J, Ekström K, et al. Risk of sudden cardiac death in cardiac sarcoidosis with or without ventricular tachycardia: A nationwide study. Circ. 2022;145:107–115. 

  1. Haptiglu S, Gardezi SKM, Azzu A, et al. Diagnosis of cardiac sarcoidosis in patients presenting with cardiac arrest or life-threatening arrhythmias. Heart. 2023;109(10):748-755. 

  1. ElRefai M, Menexi C, Roberts PR. Device Therapy in Cardiac Sarcoidosis: Current Review, Challenges, and Future Prospects. J Innov Card Rhythm Manag. 2024;15 (11):6088-6094. 

  1. Mactaggart S, Ahmed S. The role of ICDs in cases with sarcoidosis-A comprehensive review. Curr Probl Cardiol. 2024; 49(5):102483. 

Jenna Davison replied on

Abraham Augustus replied on

References

  1. Krantz MJ, Lewkowiez L, Hays H, Woodroffe MA, Robertson AD, Mehler PS.
    Torsade de pointes associated with very-high-dose methadone. Ann Intern Med. 2002;137(6):501-504. doi:10.7326/0003-4819-137-6-200209170-00010

  2. Roden DM.
    Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350(10):1013-1022. doi:10.1056/NEJMra032426

  3. Roden DM.
    Clinical practice. Long-QT syndrome. N Engl J Med. 2008;358(2):169-176. doi:10.1056/NEJMcp0706513

  4. Lempert T, Bauer M, Schmidt D.
    Syncope: a videometric analysis of 56 episodes of transient cerebral hypoxia. Ann Neurol. 1994;36(2):233-237. doi:10.1002/ana.410360217

  5. Sheldon R, Rose S, Ritchie D, et al.
    Historical criteria that distinguish syncope from seizures. J Am Coll Cardiol. 2002;40(1):142-148. doi:10.1016/S0735-1097(02)01940-X

  6. U.S. Food and Drug Administration.
    Dolophine® (methadone hydrochloride tablets) prescribing information. Revised 2018.
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/006134s045lbl.pdf

  7. Mujtaba S, Ahmed A, Turaev S, et al.
    Methadone, QTc prolongation and torsades de pointes: current concepts, management and a hidden twist in the tale? Case Rep Cardiol. 2013;2013:1-6. doi:10.1155/2013/241954

  8. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al.
    2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and prevention of sudden cardiac death. Circulation. 2018;138(13):e272-e391. doi:10.1161/CIR.0000000000000549

  9. Ehret GB, Voide C, Gex-Fabry M, et al.
    Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Arch Intern Med. 2006;166(12):1280-1287. doi:10.1001/archinte.166.12.1280

  10. Paknahad M, et al.
    QTc prolongation and torsades de pointes (TdP) in individuals undergoing methadone maintenance treatment (MMT): A systematic review and meta-analysis. Medicine (Baltimore). 2025;104(43):e45304. doi:10.1097/MD.0000000000045304

  11. Titus-Lay EN, Jaynes HA, Muensterman ET, Walroth TA, Ott CA, Desta Z, Williams G, Moe PR, Wilbrandt M, Tisdale JE.
    Methadone-associated QT interval prolongation in patients undergoing maintenance therapy in an urban opioid treatment program. Pharmacotherapy. 2021;41(2):169-178. doi:10.1002/phar.2498

Abraham Augustus replied on